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1 These authors contributed equally to this work.Ingestion of inorganic nitrate elevates blood and tissue levels of nitrite via bioconversion in the
entero-salivary circulation. Nitrite is converted to NO in the circulation, and it is this phenomenon that
is thought to underlie the beneﬁcial effects of inorganic nitrate in humans. Our previous studies have
demonstrated that oral ingestion of inorganic nitrate decreases blood pressure and inhibits the transient
endothelial dysfunction caused by ischaemia–reperfusion injury in healthy volunteers. However,
whether inorganic nitrate might improve endothelial function per se in the absence of a pathogenic stim-
ulus and whether this might contribute to the blood pressure lowering effects is yet unknown. We con-
ducted a randomised, double-blind, crossover study in 14 healthy volunteers to determine the effects of
oral inorganic nitrate (8 mmol KNO3) vs. placebo (8 mmol KCl) on endothelial function, measured by
ﬂow-mediated dilatation (FMD) of the brachial artery, prior to and 3 h following capsule ingestion. In
addition, blood pressure (BP) was measured and aortic pulse wave velocity (aPWV) determined. Finally,
blood, saliva and urine samples were collected for chemiluminescence analysis of [nitrite] and [nitrate]
prior to and 3 h following interventions. Inorganic nitrate supplementation had no effect on endothelial
function in healthy volunteers (6.9 ± 1.1% pre- to 7.1 ± 1.1% post-KNO3). Despite this, there was a signif-
icant elevation of plasma [nitrite] (0.4 ± 0.1 lM pre- to 0.7 ± 0.2 lM post-KNO3, p < 0.001). In addition
these changes in [nitrite] were associated with a decrease in systolic BP (116.9 ± 3.8 mm Hg pre- vs.
112.1 ± 3.4 mm Hg post-KNO3, p < 0.05) and aPWV (6.5 ± 0.1 m/s pre- to 6.2 ± 0.1 post-KNO3, p < 0.01).
In contrast KCl capsules had no effect on any of the parameters measured. These ﬁndings demonstrate
that although inorganic nitrate ingestion does not alter endothelial function per se, it does appear to
improve blood ﬂow, in combination with a reduction in blood pressure. It is likely that these changes
are due to the intra-vascular production of NO.
Crown Copyright  2012 Published by Elsevier Inc. Open access under CC BY license.Introduction
The healthy endothelium plays an essential role in regulating
vascular homeostasis by endowing the blood vessel wall with a
vasodilator, anti-platelet, anti-atherogenic and anti-proliferative
phenotype [1,2]. An important mediator of this beneﬁcial inﬂuence
of the endothelium is nitric oxide (NO) which is generated tonically
by endothelial NO synthase (eNOS) [3,4]. Importantly, in patients
with cardiovascular risk factors these beneﬁcial effects of the
endothelium are impaired [5]; a phenomenon termed ‘endothelial
dysfunction’. This dysfunction, at least in part, has been attributed
to a reduced synthesis and bioavailability of endothelium-derived
NO [6–8] that has been evidenced by the measurement of
reductions in the levels of NO metabolites and via the clinical
assessment of reduced endothelial function by measuringevier Inc.
alia).
Open access under CC BY liﬂow-mediated dilatation (FMD), an endothelium-dependent vaso-
dilatation response known to be mediated by NO [9].
Endothelial dysfunction often precedes symptomatic cardiovas-
cular disease [5], offering potential for measurement as a bio-
marker [10], but is thought also to be a key pathogenic event
involved in the development of disease [11]. Clinical evidence sup-
ports the view that the magnitude of the FMD response is also pre-
dictive not only of the occurrence of an event in both low- and
high-risk individuals [12–14] but also the severity of cardiovascu-
lar disease [15,16]. Therefore, identifying novel approaches that
might improve or recover NO-dependent endothelial responses
in individuals with cardiovascular disease may offer potential
therapeutic strategies worth exploring.
Recently, there has been a growing appreciation that the
inorganic nitrate ðNO3 Þ anion, either generated in vivo as an oxida-
tive metabolite of NO itself [17] or ingested through the diet (pre-
dominant dietary sources being green leafy vegetables) [18] might
offer a source of NO in the body that is independent of the conven-
tional NO synthesis pathways [19,20]. In the body nitrate anion iscense.
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into the oral cavity [21]. Here, this nitrate-rich saliva comes into
close contact with facultative anaerobes, on the dorsal surface of
the tongue, that reduce nitrate to nitrite [22]. This nitrite is then
swallowed, absorbed and distributed within the vasculature, rais-
ing systemic nitrite levels [23,24]; a circuit often described as the
entero-salivary circuit [23,25]. Within the circulation, nitrite is
then reduced to bioactive NO by one of a number of potential
enzymatic and non-enzymatic processes [26], a phenomenon sup-
ported by demonstration of associated elevations of plasma cyclic
guanosine monophosphate (cGMP) levels, thought to be the most
sensitive indicator of endogenous NO generation [27]. Importantly,
our previous studies have demonstrated that ingestion of inorganic
nitrate lowers blood pressure (BP) and also prevents the endothe-
lial dysfunction caused by an ischaemia–reperfusion injury in the
forearm of healthy volunteers [23,24]. However, whether these ef-
fects of inorganic nitrate relate simply to provision of NO or
whether alteration of endothelial function per se (as has been evi-
denced for other albeit unrelated dietary-based interventions
[28,29]) might underlie these effects is yet unknown and an issue
we investigated in the study described herein.Materials and methods
Volunteers
The studies were granted full ethical approval by the local re-
search ethics committee. All participants gave informed consent
after satisfying the inclusion criteria: healthy male or female adults
aged between 18 and 45 years; systolic blood pressure (SBP)
<140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg; body
mass index (BMI) 18–30 kg/m2, non-smoker and no systemic med-
ication (except the oral contraceptive pill). Volunteers were in-
structed to eat a low nitrate diet (i.e. no green leafy vegetables or
cured meats) and avoid strenuous exercise the day before study
visits. In addition, volunteers were fasted overnight before all
study visits.Study protocol
Power analyses, based upon our previous ﬁndings [23,24]
indicated that to obtain signiﬁcant elevation (2-fold) of circulating
nitrite levels an n of 12 would be sufﬁcient using an a = 0.05,
b = 0.90 and a standard deviation of 0.37 lM. We conducted a ran-
domised, placebo-controlled, double blind, cross-over, clinical
study in 14 healthy volunteers (additional two to account for po-
tential dropouts), who received either 8 mmol potassium nitrate
(KNO3, Martindale Pharmaceuticals, Ipswich, UK) or matched
potassium chloride (KCl, Martindale Pharmaceuticals, Ipswich,
UK) placebo control, and completed the cross-over limb between
7 and 28 d later. Interventions were taken with 2 slices of dry
wholemeal toast and 250 ml low-nitrate containing water (Zep-
brook Ltd., London, UK). BP was measured and urine, saliva and
plasma samples were collected for analysis of [nitrate] and [nitrite]
(collectively termed ‘NOx’) by ozone chemiluminescence. FMD of
the brachial artery was measured using ultrasound and arterial
compliance by measurement of aortic pulse wave velocity (aPWV).
All studies took place in a quiet, temperature controlled (24–26 C)
environment. All measures were performed at baseline and at 3 h
post intervention. This 3 h time point was chosen since our previ-
ous ﬁndings have demonstrated that circulating levels of nitrite
and the associated bioactivity (i.e. decrease in BP, prevention of
ischaemia–reperfusion induced endothelial dysfunction, etc.) peak
at this time following nitrate ingestion [23,24].Study techniques
Blood pressure measurement
All BP and heart rate (HR) measurements were performed in
triplicate in the seated position using an Omron 705IT according
to established guidelines [30]. Both investigators and participants
were blinded to the readings by means of laminated coverings
for the machine and printer. For the purpose of analysis, the means
of the 2nd and 3rd readings were used.
FMD measurement
Endothelial function was assessed by measuring brachial artery
diameter in response to reactive hyperaemia as previously de-
scribed [23,31]. Brieﬂy, a B-mode scan of the brachial artery was
obtained in longitudinal section above the antecubital fossa using
a 7.0 MHz linear array transducer and a standard Acuson Aspen
system (Acuson, Mountain View, UK). Arterial diameter over a 1–
2 cm section was determined for each image with the use of auto-
matic edge-detection software (Vascular Research Tools, Medical
Imaging Applications LLC Iowa City, USA) and synchronised by 3-
lead electrocardiography to the R-wave of the QRS complex. Blood
ﬂow was altered in the brachial artery by a 7 cm-wide BP cuff
placed immediately below the antecubital fossa around the fore-
arm. After 1 min of baseline ﬂow, the cuff was inﬂated to
300 mm Hg for 5 min and released, resulting in a brief episode of
reactive hyperaemia and changes in brachial artery diameter in re-
sponse to blood ﬂow were assessed for an additional 5 min. Bra-
chial artery diameter and brachial artery dilation, expressed as
percentage increase from baseline diameter, were determined
using the software Vascular Analysis Tools (Medical Imaging Appli-
cations, LLC Iowa City, USA).
aPWV measurement
A Vicorder device (Skidmore Medical Ltd., Bristol, UK) was used
to simultaneously record the pulse wave from the carotid and fem-
oral arteries using an oscillometric method [32]. A small, inﬂatable
neck pad is placed directly over a single carotid artery and secured
around the neck by a Velcro tab and a cuff is placed around the sub-
ject’s ipsilateral upper thigh. Both carotid and femoral cuffs are in-
ﬂated automatically to 65 mm Hg and the corresponding
oscillometric signal from each cuff is digitally analysed to extract
the pulse-time delay. The distance between the sternal notch and
the thigh cuff is measured and used as a standard estimate for the
aortic length. From these measurements aortic pulse wave velocity
(aPWV) can be derived as aPWV = aortic distance/pulse time delay.
Blood sampling
Blood was sampled into separate pre-chilled EDTA tubes for
NOx, through a 21-gauge butterﬂy needle inserted into the antecu-
bital vein. Blood samples were immediately centrifuged (1300g,
4 C, 10 min), plasma was separated and deproteinated by ﬁltra-
tion (centrifugation 14000g, 4 C, 60 min) using Vivaspin 500,
3 kDa ﬁlters (Sartorius Biotech, Aubagne, France) and the ﬁltrate
stored at 80 C, until analysis by ozone chemiluminescence.
Urine and saliva sampling
Mid-stream urine samples were collected into sterile containers
and an aliquot stored at 80 C until analysis at a later date.
Unstimulated saliva was collected into sterile eppendorfs and cen-
trifuged (14000g, 4 C, 10 min) and the supernatant was collected
and stored at 80 C until analysis at a later date.
Measurement of plasma [NOx]
[NOx] was measured by ozone-based chemiluminescence as
previously described [17]. Brieﬂy, to determine total [NOx],
samples were added to 0.1 M vanadium (III) chloride in 1 M
Table 1
Baseline demographic, haemodynamic and analytical parameters.
Characteristic Placebo limb Inorganic
nitrate limb
Signiﬁcance
Subjects (n) 14
Age (years) 27.9 ± 1.8
BMI (kg/m2) 24.5 ± 0.9
Baseline SBP (mm Hg) 115.1 ± 3.4 116.9 ± 3.8 p = 0.37
Baseline DBP (mm Hg) 66.8 ± 1.5 67.7 ± 1.4 p = 0.54
Plasma ½NO3  (lM) 28.5 ± 2.4 31.1 ± 4.2 p = 0.54
Plasma ½NO2  (lM) 0.39 ± 0.03 0.34 ± 0.03 p = 0.20
Signiﬁcance shown in the last column for paired Student’s t-test. Data are shown as
mean ± SEM values (n = 14).
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determined by addition of samples to 0.09 M potassium iodide inFig. 1. Inorganic nitrate supplementation elevates NOx in healthy volunteers. The effects
circulating plasma (a) [nitrate] and (b) [nitrite]; salivary (c) [nitrate] and (d) [nitrite]; and
between groups as ⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 following 1-way ANOVA. Data are express
Table 2
Brachial artery diameter across all 4 visits.
Placebo limb
Characteristic Pre- 3 h post
Baseline brachial artery diameter (mm) 3.3 ± 0.2 3.4 ± 0.2
No signiﬁcance found with Bonferroni post hoc tests following 1-way ANOVA (n = 13).glacial acetic acid under nitrogen at room temperature. [Nitrate]
was calculated by subtraction of the [nitrite] from [NOx].
Statistical analysis
The data were analysed using Graphpad Prism software version
5. All data are expressed as a mean ± SEM. For FMD and aPWV re-
sponses, data were compared using paired Student t-tests. Plasma,
urine and saliva [NOx] were analysed using one-way ANOVA and
Bonferroni post hoc tests for comparison of individual treatments.
A p-value <0.05 was considered to be signiﬁcant for all analyses.
Results
All interventions were tolerated without adverse effects.
Volunteer baseline demographics are presented in Table 1 andof inorganic nitrate supplementation (KNO3, 8 mmol) or placebo (KCl, 8 mmol) on
urinary (e) [nitrate] and (f) [nitrite]. Signiﬁcance shown for Bonferroni post hoc tests
ed as mean ± SEM (n = 14).
Inorganic nitrate limb
Pre- 3 h post Signiﬁcance
3.4 ± 0.2 3.4 ± 0.2 p = NS for all comparisons
Fig. 2. Inorganic nitrate does not alter endothelial function in healthy volunteers.
The effects of inorganic nitrate supplementation (KNO3, 8 mmol) or placebo (KCl,
8 mmol) on FMD. No signiﬁcance found for comparisons between groups using
Bonferroni post hoc tests, following 1-way ANOVA. Data are expressed as
mean ± SEM (n = 13).
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or baseline [NOx] between the two limbs of the study. For one vol-
unteer, FMD could not be reliably measured due to technical
difﬁculties.Inorganic nitrate supplementation raised [NOx]
At 3 h following ingestion of inorganic nitrate there was a sig-
niﬁcant elevation in plasma, salivary and urinary [nitrate] and [ni-
trite] (Fig. 1). There were no changes in plasma, salivary or urinary
[NOx] after placebo (Fig. 1) (n = 14 for all).Fig. 3. Inorganic nitrate reduces SBP and aPWV in healthy volunteers. The effects of inor
(b) DBP, (c) HR and (d) aPWV. Signiﬁcance shown for Bonferroni post hoc tests betwe
mean ± SEM (n = 14).Inorganic nitrate supplementation does not alter endothelial function
There was no signiﬁcant difference in baseline brachial artery
diameter between the groups, with a mean diameter of
3.4 ± 0.2 mm (Table 2). In addition, there was no evidence of
change in the FMD response after either inorganic nitrate supple-
mentation or placebo (n = 13 for both) (Fig. 2).
Inorganic nitrate supplementation reduces BP and aPWV
There was a signiﬁcant reduction in systolic BP (SBP) after inor-
ganic nitrate supplementation (DSBP = 4.9 ± 1.4 mm Hg, p < 0.05,
Fig. 3a) that was not apparent after placebo (DSBP = 0.4 ± 1.3 mm
Hg; Fig. 3a). There were no signiﬁcant changes in diastolic BP (DBP)
or heart rate (HR) after inorganic nitrate supplementation or pla-
cebo (Fig. 3b and c). Similarly to SBP, aPWV was signiﬁcantly re-
duced after inorganic nitrate supplementation but unchanged
after placebo (Fig. 3d).
Discussion
Fruit and vegetable rich diets are associated with reduced risk
of cardiovascular disease [33,34]. Prospective clinical studies
investigating the potential of dietary anti-oxidants in protecting
against cardiovascular disease have failed to reproduce the same
beneﬁcial effects [35–37]. Such observations have stimulated the
search for other possible candidates that might underlie the bene-
ﬁts of fruit and vegetable rich diets. This search has lead some to
suggest that dietary (inorganic) nitrate may be responsible
[18,20,38]. Herein, we demonstrate that whilst inorganic nitrate
supplementation does not alter endothelial function per se that it
does improve vascular compliance; an effect that is also associated
with a decrease in BP, in healthy volunteers. We suggest that theseganic nitrate supplementation (KNO3, 8 mmol) or placebo (KCl, 8 mmol) on (a) SBP,
en groups as ⁄p < 0.05, ⁄⁄p < 0.01 following 1-way ANOVA. Data are expressed as
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healthy diets.
The non-invasive assessment of endothelial function has proven
to be a useful surrogate marker with which to assess both general
cardiovascular health and risk of cardiovascular events [7]; in par-
ticular, the measurement of ultrasound FMD [12,39]. Our previous
studies have shown that dietary nitrate and inorganic nitrate salts
are able to prevent the decreases in FMD, as a reﬂection of endo-
thelial dysfunction, induced by ischaemia–reperfusion injury in
healthy volunteers [23,24]. However, whether these effects related
to prevention of the damage caused by the pathogenic insult or
whether the dietary nitrate intervention improved endothelial
function per sewere not determined. Here, we show in healthy vol-
unteers that despite elevations in systemic [nitrite] following
ingestion of an 8 mmol dose of KNO3 salt, there was no evidence
of alterations in endothelial function. Previous studies have shown
that certain acute interventions can enhance FMD responses in
individuals classiﬁed as healthy volunteers. For instance following
an acute intervention of ﬂavonoid-rich green tea [29] or dark choc-
olate [28] FMD responses in healthy volunteers were enhanced; ef-
fects proposed to contribute substantially to the apparent
protective effects of these dietary substances against cardiovascu-
lar disease [40,41]. Such observations indicate that the absence of
an effect of the intervention in this study was not simply due to the
fact that FMD responses cannot be enhanced in healthy volunteers.
Interestingly, enhanced endothelial NO synthesis or bioavailability
has been implicated as underlying the improvements in FMD in
response to a number of distinct dietary constituents [42,43]. How-
ever, studies attempting to directly modulate endogenous NO-gen-
erating pathways, such as acute L-arginine (eNOS substrate)
supplementation have failed to alter FMD responses in healthy vol-
unteers [44].
This lack of effect of nitrate supplementation on endothelial
function was not related to a lack of bioactivity since, as in other
studies [23–25], inorganic nitrate supplementation reduced SBP
by 4.9 mmHg, 3 h post intervention; an effect that is directly cor-
related with elevations in circulating nitrite concentrations
[23,24]. In this study we chose to use a dose of 8 mmol KNO3 to re-
ﬂect the dose that one might consume in a vegetable-rich meal
[18,38,45]. In addition this dose was chosen since it is an interme-
diate dose between 4 and 12 mmol KNO3 which we have previ-
ously shown to cause dose-dependent rises in circulating nitrite
levels with dose-dependent reductions in SBP in healthy
volunteers (by 2 and 5.6 mm Hg, respectively) [24]. These
BP-lowering effects of 8 mmol KNO3 lend further support for a
dose-response relationship of inorganic nitrate supplementation
with respect to BP lowering.
Our studies also demonstrated an additional modest yet signif-
icant reduction in aPWV, which is a measure of arterial compli-
ance. Arterial compliance in large, elastic arteries is determined
by both the distending pressure and the intrinsic wall properties
[46]. It is unlikely that an acute administration of inorganic nitrate
alters structural properties and therefore the increase in compli-
ance is most likely a consequence of alterations in the distending
pressure in the aorta. Previous studies have shown similar ﬁndings
where acute alterations of endogenous NO levels alter BP and vas-
cular compliance concomitantly. Chowienczyk and colleagues
demonstrated that administration of organic nitrovasodilators pro-
duced a very rapid reduction in BP in healthy volunteers associated
with an increased arterial compliance [47]. Similarly, acute inhibi-
tion of NO synthesis using the NOS inhibitor L-NMMA produced lo-
cal reductions in arterial compliance [48].
Arterial compliance as measured by aPWV is a strong predictor
of future cardiovascular mortality [49] and has been adopted as an
important measure of cardiovascular risk prediction schemes [50].
Whether the effects of acute inorganic nitrate supplementation onarterial compliance might be sustained with chronic ingestion and
whether such an effect might alter hypertension and cardiovascu-
lar risk are unknown. However, our research provides further sup-
port for encouraging such investigations.
Limitations
Although our study had a small sample size, we were ade-
quately powered to detect changes in circulating plasma [nitrite]
and BP changes after inorganic nitrate supplementation. Similarly,
we had chosen to study volunteers at 3 h post intervention based
upon our previous studies demonstrating peak [nitrite] elevations
and BP responses after nitrate supplementation at 3 h post inter-
vention and importantly protection against ischaemia–reperfu-
sion-induced endothelial dysfunction [23,24]. However, it is
possible that changes in basal FMD responses occurred at earlier
or indeed later time-points.
Conclusion
These ﬁndings demonstrate that although inorganic nitrate
ingestion does not alter endothelial function per se, it does improve
blood ﬂow, in combination with a reduction in blood pressure. It is
likely that these changes are due to the production of NO that
likely directly relaxes vascular smooth muscle and therefore de-
creases aPWV.
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